CMS Projects that Drug Spending and Drug Prices Will Keep Rising Through 2030

CMS predicts that U.S. retail prescription drug spending will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.

Please Login or Become a Paid Subscriber to

Read More »

News Alert

HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy

HRSA has referred Boehringer Ingelheim to the HHS Inspector General for possible imposition of civil monetary penalties over BI's conditions on 340B pricing when hospitals use contract pharmacies.

The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”

Please Login or Become

Read More »

Arkansas Health Centers and Community Hospital Want Role in Challenging PhRMA’s Lawsuit Over State’s Novel 340B Contract Pharmacy Law

Mid Delta Health Center is a member of Community Health Centers of Arkansas, which wants to intervene in PhRMA's lawsuit challenging the state's one-of-a-kind law protecting 340B contract pharmacy arrangements.

Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.

Please Login or Become a Paid Subscriber to View

Read More »

BioComp Providing Refunds for 340B Overcharges Spanning a Whopping 8 Years

Following a HRSA audit, BioComp Pharma is offering 340B covered entities refunds on six products for overcharges spanning eight years.

Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.

Please Login

Read More »

HIV/AIDS Advocates Protest in Front of Gilead HQ Against Company’s New 340B Contract Pharmacy Policy

AHF held a demonstration in front of Gilead's headquarters protesting the company’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

AIDS Healthcare Foundation (AHF), the world’s largest AIDS provider organization, held a demonstration yesterday in front of drug manufacturer Gilead’s San Francisco Bay area headquarters protesting the company’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C

Read More »

Could J&J’s Decision to Limit 340B Contract Pharmacy Spur Congress to Act?

Could Johnson & Johnson's conditions on 340B drug sales to hospitals involving contract pharmacy be the thunderclap that rouses Congress?

J&J is the world’s biggest drug company. Its decision to restrict 340B pricing when hospitals use contract pharmacies could be a thunderclap that rouses Congress.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert

Johnson & Johnson Becomes the 16th Drug Manufacturer to Restrict 340B Contract Pharmacy

Johnson & Johnson is the 16th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert

Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”

NACHC called Gilead's 340B pricing conditions on Vosevi and three of its other hepatitis C drugs "the latest example of corporate greed from a pharmaceutical company."

The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from

Read More »

Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy

Harvoni is one of the four hepatitis C drugs that will face restrictions under Gilead's new 340B contract pharmacy policy.

HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Please Login or Become

Read More »
Generic selectors
Exact matches only
Search in title
Search in content